Funder: National Institutes of Health
Due Dates: June 16, 2025 (New) | July 16, 2025 (Renewal/Resubmission/Revision) | October 16, 2025 (New) | November 16, 2025 (Renewal/Resubmission/Revision) | February 16, 2026 (New) | March 16, 2026 (Renewal/Resubmission/Revision) | June 16, 2026 (New) | July 16, 2026 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year; max project period 2 years.
Summary: Supports secondary analysis and integration of existing data to elucidate cancer risk and related outcomes; clinical trials are not allowed.
Key Information: No new data collection except up to 10% of budget for validation; foreign and domestic applicants eligible; limited to non-clinical trial research.